Profile data is unavailable for this security.
About the company
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-7.12m
- Incorporated2014
- Employees10.00
- LocationMonopar Therapeutics Inc1000 Skokie Blvd Ste 350WILMETTE 60091-1146United StatesUSA
- Phone+1 (847) 388-0349
- Fax+1 (302) 655-5049
- Websitehttps://www.monopartx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Imunon Inc | 0.00 | -18.08m | 14.83m | 33.00 | -- | 2.59 | -- | -- | -1.92 | -1.92 | 0.00 | 0.398 | 0.00 | -- | -- | 0.00 | -94.15 | -50.18 | -132.90 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
Inhibitor Therapeutics Inc | 0.00 | -3.02m | 14.95m | 3.00 | -- | 3.61 | -- | -- | -0.0175 | -0.0175 | 0.00 | 0.024 | 0.00 | -- | -- | 0.00 | -34.83 | 27.48 | -34.99 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
AIM ImmunoTech Inc | 201.00k | -28.05m | 15.27m | 26.00 | -- | 2.50 | -- | 75.95 | -0.5703 | -0.5703 | 0.004 | 0.1068 | 0.0082 | -- | 12.18 | 7,730.77 | -113.70 | -45.64 | -149.16 | -48.35 | 71.14 | -231.75 | -13,952.74 | -11,695.01 | -- | -- | 0.3018 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
Bioxytran Inc | 0.00 | -3.51m | 15.50m | 2.00 | -- | -- | -- | -- | -0.023 | -0.023 | 0.00 | -0.0023 | 0.00 | -- | -- | -- | -2,635.88 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -20.68 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
Protext Mobility Inc | 750.00 | -2.21m | 15.82m | 4.00 | -- | -- | -- | 21,098.93 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
Monopar Therapeutics Inc | 0.00 | -7.12m | 15.98m | 10.00 | -- | 2.62 | -- | -- | -2.31 | -2.31 | 0.00 | 1.73 | 0.00 | -- | -- | 0.00 | -81.33 | -54.07 | -102.31 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
Athira Pharma Inc | 0.00 | -113.45m | 16.54m | 65.00 | -- | 0.1985 | -- | -- | -2.97 | -2.97 | 0.00 | 2.17 | 0.00 | -- | -- | 0.00 | -71.06 | -30.73 | -83.81 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
Galecto Inc | 0.00 | -25.43m | 16.55m | 13.00 | -- | 0.6098 | -- | -- | -23.45 | -23.45 | 0.00 | 21.74 | 0.00 | -- | -- | 0.00 | -59.06 | -48.46 | -75.34 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
Mira Pharmaceuticals Inc | 0.00 | -12.78m | 16.55m | 3.00 | -- | 7.46 | -- | -- | -0.8562 | -0.8562 | 0.00 | 0.1501 | 0.00 | -- | -- | 0.00 | -373.77 | -- | -737.47 | -- | -- | -- | -- | -- | -- | -3.17 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
Evaxion Biotech A/S - ADR | 278.00k | -15.21m | 16.67m | 49.00 | -- | 12.91 | -- | 59.97 | -36.98 | -36.98 | 0.1048 | 0.2316 | 0.0174 | -- | 0.3493 | 5,673.47 | -95.08 | -100.11 | -126.11 | -131.65 | -- | -- | -5,469.42 | -131,560.30 | -- | -- | 0.8933 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
Cell Source Inc | 0.00 | -6.45m | 16.78m | -- | -- | -- | -- | -- | -0.1627 | -0.1627 | 0.00 | -0.413 | 0.00 | -- | -- | -- | -1,300.91 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -5.14 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
BioVie Inc | 0.00 | -37.18m | 16.88m | 18.00 | -- | 0.8891 | -- | -- | -9.63 | -9.63 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -94.32 | -456.35 | -149.75 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.2969 | -- | -- | -- | -92.67 | -- | -- | -- |
Ibio Inc | 50.00k | -17.13m | 16.99m | 26.00 | -- | 0.6749 | -- | 339.77 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
Aprea Therapeutics Inc | 1.28m | -12.93m | 17.00m | 7.00 | -- | 0.665 | -- | 13.33 | -3.03 | -3.03 | 0.2898 | 4.95 | 0.0435 | -- | -- | 182,241.40 | -44.09 | -68.66 | -50.11 | -77.19 | -- | -- | -1,013.41 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
Holder | Shares | % Held |
---|---|---|
Millennium Management LLCas of 31 Mar 2024 | 192.38k | 1.10% |
Geode Capital Management LLCas of 30 Jun 2024 | 60.04k | 0.34% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 45.17k | 0.26% |
HRT Financial LLCas of 31 Mar 2024 | 32.11k | 0.18% |
Gerber LLCas of 30 Jun 2024 | 28.01k | 0.16% |
Virtu Americas LLCas of 30 Jun 2024 | 18.84k | 0.11% |
Rappaport Reiches Capital Management LLCas of 30 Jun 2024 | 10.70k | 0.06% |
Tower Research Capital LLCas of 31 Mar 2024 | 7.86k | 0.05% |
Strategic Advisers LLCas of 31 Mar 2024 | 5.50k | 0.03% |
NewEdge Advisors LLCas of 31 Mar 2024 | 3.00k | 0.02% |